The year 2024 was marked by economic-financial and socio-political convulsions, which accentuated Romania's vulnerabilities ...

This time I’m going to focus on one company and its view on pharma’s digital commercial strategy ... was the high level of uncertainty about its effects. In March 2020 Pfizer began ...

CSG® today released its 2025 State of the Customer Experience Report, which identifies four winning strategies for brands to begin tangibly improving their customer experience (CX) and earn customer ...

Pfizer faces revenue decline from patent expirations, profitability challenges, and bearish technicals. Learn why PFE stock ...

All this negativity, however, does open up an opportunity for investors to buy the stock at a discount. Despite being a top ...

Pfizer faces stagnant revenue and patent cliffs. Learn why I downgraded PFE stock to Strong Sell despite a 24.7% YoY growth ...

Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug ...

Bullish option flow detected in Pfizer (PFE) with 70,941 calls trading, 1.3x expected, and implied vol increasing over 1 point to 23.18%. Feb-25 25 calls and 2/28 weekly 25 puts are the most ...

Pfizer (PFE) and Astellas Pharma announced additional follow-up results from the Phase 3 EV-302 clinical trial evaluating the efficacy and safety of PADCEV, or enfortumab vedotin-ejfv, a Nectin-4 ...